Chinese expert consensus statement on the clinical application of AFP/AFP‐L3%/DCP using GALAD and GALAD‐like algorithm in HCC

Abstract

AbstractBackgroundPrimary hepatocellular carcinoma (HCC) is one of the most prevalent world‐wide malignancies. Half of the newly developed HCC occurs in China. Optimizing the strategies for high‐risk surveillance and early diagnosis are pivotal for improving 5‐year survival. Constructing the scientific non‐invasive detection technologies feasible for medical and healthcare institutions is among the key routes for elevating the efficacies of HCC identification and follow‐up.ResultsBased on the Chinese and international guidelines, expert consensus statements, literatures and evidence‐based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple‐biomarker (AFP, AFP‐L3%, DCP) based GALAD, GALAD like models for liver cancer.ConclusionsThe compile of this consensus statement aims to address and push the reasonable application of the triple‐biomarker (AFP, AFP‐L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.